Cytolytic T Lymphocyte-Associated Antigen-4 and the TCRζ/CD3 Complex, But Not CD28, Interact with Clathrin Adaptor Complexes AP-1 and AP-2
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The negative signaling receptor cytolytic T lymphocyte-associated Ag-4 (CTLA-4) resides primarily in intracellular compartments such as the Golgi apparatus of T cells. However, little is known regarding the molecular mechanisms that influence this accumulation. In this study, we demonstrate binding of the clathrin adaptor complex AP-1 with the GVYVKM motif of the cytoplasmic domain of CTLA-4. Binding occurred primarily in the Golgi compartment of T cells, unlike with AP-2 binding that occurs mostly with cell surface CTLA-4. Although evidence was not found to implicate AP-1 binding in the retention of CTLA-4 in the Golgi, AP-1 appears to play a role in shuttling of excess receptor from the Golgi to the lysosomal compartments for degradation. In support of this, increased CTLA-4 synthesis resulted in an increase in CTLA-4/AP-1 binding and a concomitant increase in the appearance of CTLA-4 in the lysosomal compartment. At the same time, the level of intracellular receptor was maintained at a constant level, suggesting that CTLA-4/AP-1 binding represents one mechanism to ensure steady state levels of intracellular CTLA-4 in T cells. Finally, we demonstrate that the TCRζ/CD3 complex (but not CD28) also binds to AP-1 and AP-2 complexes, thus providing a possible link between these two receptors in the regulation of T cell function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 1×
“Consistent with this negative function, T cells from CTLA-4-deficient mice are hyperresponsive to anti-CD3 ligation, and show extensive lymphadenopathy (11, 12).”
BackgroundLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 1×
“Consistent with this negative function, T cells from CTLA-4-deficient mice are hyperresponsive to anti-CD3 ligation, and show extensive lymphadenopathy (11, 12).”
BackgroundCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“Although CD28 augments lymphokine production and the T cell response (1, 3, 6–8), Ab-blocking studies first suggested that CTLA-4 might negatively regulate the activation process (9, 10).”
BackgroundCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 1×
“Although CD28 augments lymphokine production and the T cell response (1, 3, 6–8), Ab-blocking studies first suggested that CTLA-4 might negatively regulate the activation process (9, 10).”
BackgroundSchwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293
Molecular Basis of T Cell Inactivation by CTLA-4
Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D. K., Zhang, W., Straus, D., Samelson, L. E., Thompson, C. B., & Bluestone, J. A. (1998) · Science · doi:10.1126/science.282.5397.2263 · Cited by 684
[16] Isolation of subcellular organelles
Storrie, B., & Amadden, E. (1990) · Methods in Enzymology · doi:10.1016/0076-6879(90)82018-w · Cited by 555 · cited 2×
“In addition, the purity of lysosomes was verified by the lysosomal marker enzyme b-hexosaminidase, as described (50).”
MethodRegulation of T Cell Receptor Signaling by Tyrosine Phosphatase SYP Association with CTLA-4
Marengère, L. E. M., Waterhouse, P., Duncan, G. S., Mittrücker, H.-W., Feng, G.-S., & Mak, T. W. (1996) · Science · doi:10.1126/science.272.5265.1170 · Cited by 551
Stamnes, M. A., & Rothman, J. E. (1993) · Cell · doi:10.1016/0092-8674(93)90277-w · Cited by 416
Structural relationships between clathrin assembly proteins from the Golgi and the plasma membrane.
Ahle, S., Mann, A., Eichelsbacher, U., & Ungewickell, E. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02897.x · Cited by 354
Cited by
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
“While CTLA-4 lacks dileucine motifs, it has a Gly–Val–Tyr–Val–Lys–Met (GVYVKM) motif for AP-2 binding (49).”
BackgroundSelf-citationThe emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
Lo, B., Zhang, K., Lu, W., Zheng, L., Zhang, Q., Kanellopoulou, C., Zhang, Y., Liu, Z., Fritz, J. M., Marsh, R., et al. (2015) · Science · doi:10.1126/science.aaa1663 · Cited by 675
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Egen, J. G., & Allison, J. P. (2002) · Immunity · doi:10.1016/s1074-7613(01)00259-x · Cited by 535
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION
Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 518
Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.
Rudd, C. E., & Schneider, H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1131 · Cited by 392
Self-citationAt the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
Confusing signals: Recent progress in CTLA-4 biology
Walker, L. S. K., & Sansom, D. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.001 · Cited by 361
CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms
Ligers, A., Teleshova, N., Masterman, T., Huang, W.-X., & Hillert, J. (2001) · Genes & Immunity · doi:10.1038/sj.gene.6363752 · Cited by 359
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
Contardi, E., Palmisano, G. L., Tazzari, P. L., Martelli, A. M., Falà, F., Fabbi, M., Kato, T., Lucarelli, E., Donati, D., Polito, L., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21155 · Cited by 324
CTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 297
The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology
Sansom, D. M., & Walker, L. S. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00419.x · Cited by 293
What's the difference between CD80 and CD86?
Sansom, D. M., Manzotti, C. N., & Zheng, Y. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00111-x · Cited by 289
CTLA4 gene polymorphism and autoimmunity
Gough, S. C. L., Walker, L. S. K., & Sansom, D. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00249.x · Cited by 288
Impairment of NK Cell Function by NKG2D Modulation in NOD Mice
Ogasawara, K., Hamerman, J. A., Hsin, H., Chikuma, S., Bour-Jordan, H., Chen, T., Pertel, T., Carnaud, C., Bluestone, J. A., & Lanier, L. L. (2003) · Immunity · doi:10.1016/s1074-7613(02)00505-8 · Cited by 276
Structural Analysis of CTLA-4 Function In Vivo
Masteller, E. L., Chuang, E., Mullen, A. C., Reiner, S. L., & Thompson, C. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5319 · Cited by 252
CTLA-4 trafficking and surface expression
Valk, E., Rudd, C. E., & Schneider, H. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.011 · Cited by 177
“Several intracellular proteins bind to the Y201VKM sequence including the lipid kinase phosphatidylinositol 3-kinase (PI3K) [30], the phosphatases SHP-2 and PP2A [14-18] and clathrin adaptor proteins AP-1 and AP-2 [31-33] (Figure 1).”
BackgroundSelf-citationCTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions
Laurent, S., Carrega, P., Saverino, D., Piccioli, P., Camoriano, M., Morabito, A., Dozin, B., Fontana, V., Simone, R., Mortara, L., et al. (2010) · Human Immunology · doi:10.1016/j.humimm.2010.07.007 · Cited by 121
Schneider, H., Smith, X., Liu, H., Bismuth, G., & Rudd, C. E. (2008) · European Journal of Immunology · doi:10.1002/eji.200737423 · Cited by 116
Self-citationValk, E., Leung, R., Kang, H., Kaneko, K., Rudd, C. E., & Schneider, H. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.024 · Cited by 78
Self-citationTyrosine Phosphatase SHP-2 Binding to CTLA-4: Absence of Direct YVKM/YFIP Motif Recognition
Schneider, H., & Rudd, C. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2234 · Cited by 78
Self-citationThe role of immune checkpoints in antitumor response: a potential antitumor immunotherapy
Mejía-Guarnizo, L. V., Monroy-Camacho, P. S., Turizo-Smith, A. D., & Rodríguez-García, J. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298571 · Cited by 48
Metadata
- Authors
- Schneider, H., Martin, M., Agarraberes, F. A., Yin, L., Rapoport, I., Kirchhausen, T., & Rudd, C. E.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-08
- Volume
- 163
- Issue
- 4
- Pages
- 1868-1879
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W4313422289
- Cited by
- 125
- References
- 13
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.